Literature DB >> 2858699

Ketoconazole therapy in Cushing's disease.

A Angeli, R Frairia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2858699     DOI： 10.1016/s0140-6736(85)91482-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

Review 2.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

3.  Failure of long-term therapy with sodium valproate in Cushing's disease.

Authors:  A Colao; R Pivonello; F S Tripodi; F Orio; D Ferone; G Cerbone; C Di Somma; B Merola; G Lombardi
Journal:  J Endocrinol Invest       Date:  1997 Jul-Aug       Impact factor: 4.256

Review 4.  Medical therapy of Cushing's disease.

Authors:  Lynnette K Nieman
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 5.  The endocrine effects of ketoconazole.

Authors:  N Sonino
Journal:  J Endocrinol Invest       Date:  1986-08       Impact factor: 4.256

6.  Ketoconazole treatment in Cushing's disease. Effect on the circadian profile of plasma ACTH and cortisol.

Authors:  M Terzolo; M Panarelli; A Piovesan; M Torta; P Paccotti; A Angeli
Journal:  J Endocrinol Invest       Date:  1988-11       Impact factor: 4.256

7.  Hormonal and immunological pattern in a patient with acquired immunodeficiency syndrome related complex and Cushing's syndrome.

Authors:  R Rossi; A P Tommaselli; N Panza; M R Ghiggi; G Rezza; M Giuliani; B Suligoi; R De Mercato; G Lombardi
Journal:  J Endocrinol Invest       Date:  1992-12       Impact factor: 4.256
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.